Current developments in PI3K-based anticancer agents: Designing strategies, biological activity, selectivity,...

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• The phosphatidylinositol-3 kinase (PI3K) pathway is frequently dysregulated in various cancers, driving tumor cell survival, angiogenesis, and metastasis.
• Mutations or overexpression of PI3K isoforms (α, β, δ, γ) contribute to therapeutic resistance, highlighting the need for novel inhibitors.
• Existing PI3K inhibitors have faced challenges due to toxicity and withdrawn indications, necessitating innovative drug development strategies.

Purpose of the Study:

• To review the current landscape of PI3K inhibitors for cancer therapy.
• To analyze the development techniques, structure-activity relationships (SAR), and docking insights of PI3K inhibitors.
• To identify future directions for developing effective and safe PI3K-targeting drugs.

Main Methods:

• Comprehensive literature review of PI3K pathway inhibitors.
• Analysis of medicinal chemistry scaffolds and their structure-activity relationships.
• Examination of clinical trial data and reasons for drug withdrawal.
• Inclusion of docking insights for rational drug design.

Main Results:

• Numerous PI3K inhibitors utilizing diverse scaffolds (e.g., thiazole, triazine, benzimidazole) have been investigated.
• Understanding of SAR and docking provides a basis for designing isoform-specific and potent inhibitors.
• Challenges remain in overcoming resistance and mitigating adverse effects associated with PI3K inhibition.

Conclusions:

• Targeting the PI3K pathway remains a promising strategy in oncology.
• Further research into novel scaffolds, SAR, and rational design is crucial for developing next-generation PI3K inhibitors.
• Future efforts should focus on improving efficacy, safety, and overcoming resistance mechanisms for better patient outcomes.